Joint Development of a Two-way Interface Enabling Wired and Wireless
Communication Now Underway
IRVINE, Calif. and JERUSALEM, Aug. 11 /PRNewswire-FirstCall/ -- Masimo
(Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through
Motion and Low-Perfusion pulse oximetry, and Oridion (SIX Swiss Exchange:
ORIDN), a global innovator of capnography monitoring solutions, today jointly
announced an agreement to establish compatibility and connectivity between
Oridion Capnostream(TM)20 portable bedside monitors and the Masimo Patient
SafetyNet(TM) remote monitoring and clinician notification system. The
agreement provides for joint development of a two-way interface allowing
Patient SafetyNet to retrieve, analyze, and display physiological data from
Capnostream monitors, while managing bi-directional communication and alarm
features to facilitate earlier recognition of and clinical response to adverse
respiratory events that require immediate clinical intervention.
According to a recently released HealthGrades study on patient safety in
American hospitals, failure to rescue--which is defined as death occurring
when an adverse clinical event is not recognized in time to save a patient
with serious treatable complications--is the most common and most serious
medical error at U.S. hospitals.(1) Masimo Patient SafetyNet was specifically
developed to provide a new level of safety to patients on general care floors,
where nurse-to-patient ratios can often preclude the level of direct
surveillance required and recommended to preempt adverse events.
The key to a successful patient rescue is getting the right information to
the right clinician at the right time. This means that accurate, reliable, and
actionable patient data is necessary for rapid response or patient safety
solutions to be effective. Oridion Capnostream monitors feature two
industry-leading technologies--Oridion's patented Microstream sidestream
Smart Capnography(TM), and Masimo SET Measure-Through Motion and
Low-Perfusion pulse oximetry--that together provide clinicians with an early
warning of a possible life-threatening deterioration in their patients'
physiological status.
Oridion Microstream technology enables the most accurate and reliable
assessment of breathing quality for patients requiring continuous ventilation
monitoring, providing clinicians with timely recognition of changes that may
lead to a decline in respiratory status or airway compromise. Masimo SET is
the most accurate and reliable pulse oximetry technology, clinically proven in
more than 100 independent and objective studies to provide the most
trustworthy SpO2 and pulse rate measurements even under the most difficult
clinical conditions, including patient motion and low peripheral perfusion.
Masimo Patient SafetyNet will be the first remote monitoring and clinician
notification system to feature Oridion's newest Smart Capnography(TM)
algorithm--Integrated Pulmonary Index(TM) (IPI)--enabling real-time tracking
and trending of EtCO2, respiration rate, pulse rate, and SpO2 for an inclusive
assessment of the patient's ventilatory status with a single index parameter.
According to Gerry Feldman, President of Oridion Systems Ltd., a
partnership between the gold standards technologies in capnography and pulse
oximetry "represents a winning combination for patients, clinicians and
hospitals alike because a change in breathing quality and oxygenation can be
important early indications that a patient may be heading for big trouble.
The ability to quickly route this vital information to a qualified caregiver
or rapid response team for appropriate clinical intervention can mean the
difference between a timely rescue and failure to rescue. Oridion Microstream
and Masimo SET technologies, together with the Masimo Patient SafetyNet
system, will arm hospitals with the accurate, real-time information they need
to make the most of their patient safety efforts."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy to partner
with Oridion to expand the variety of vital sign parameters and third-party
multi-parameter patient monitoring devices that offer real-time wireless
connectivity to the Masimo Patient SafteyNet remote monitoring and clinician
notification system. The Oridion Capnostream 20 monitor combines proven
best-in-class measurements for oxygenation and ventilation in a portable and
easy-to-use device for clinicians and patients in both hospital and outpatient
settings. Enabling full connectivity and two-way wireless communication
between Oridion Capnostream monitors and Masimo's Patient SafetyNet system
will provide additional flexibility and monitoring options for healthcare
facilities looking to advance patient safety and improve clinical outcomes."
Development of the two-way interface enabling full connectivity between
Oridion monitors and Patient SafetyNet is now underway, with completion
expected in Q4 of this year. Furthermore, existing Oridion Capnostream 20
monitors and Masimo Patient SafteyNet systems can be easily upgraded via
software to add this functionality following full commercial release of the
bi-directional interface.
About Oridion
Oridion Systems Ltd. (www.oridion.com) is a global medical device company
specializing in patient safety monitoring. The Company operates through wholly
owned subsidiaries in the United States, Europe, and Israel. Oridion develops
proprietary medical devices and patient interfaces, based on its patented
Microstream technologies, for the enhancement of patient safety through the
monitoring of the carbon dioxide (CO2) in a patient's breath. These products
provide effective, proven airway management and are used in various clinical
environments, including procedural sedation, pain management, operating rooms,
critical care units, post-anesthesia care units, emergency medical services,
transport, alternate care and other settings where patients' ventilation may
be compromised and at risk. Additional information about Oridion and its
products may be found at www.oridion.com.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET , which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO ),
methemoglobin (SpMet ), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumptions regarding the timing and availability of connectivity and a
two-way interface between Oridion Capnostream and Masimo Patient SafetyNet,
risks related to our belief that Patient SafetyNet will provide an effective
early warning system to enable timely rescue, risks related to our belief that
Masimo SET will provide sufficient sensitivity and specificity to detect
physiological abnormalities and potentially life-threatening conditions in
real-time for all patients, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included in
this press release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these forward-looking
statements or the "Risk Factors" contained in our most recent reports filed
with the SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1 (949) 297-7348
Walter Tabachnik
Oridion Systems Ltd.
+972 (2) 589-9159
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation. Capnostream and Microstream are
trademarks or registered trademarks of Oridion.
SOURCE Masimo
Web Site:
http://www.masimo.com
http://www.oridion.com